ASCLETIS-B(01672) will report in oral form at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) that the weight loss effect of ASC36_35 FDC is superior to the preclinical data of eloralintide combined with tirzepatide.

ASCLETIS-B (01672) announced that the Board of Directors will report on the preclinical data of ASC36_35 FDC, a once-monthly injectable combination formulation of ASC36 (a peptide insulin receptor agonist) and ASC35 (a peptide GLP-1R/GIPR agonist) for the treatment of obesity in a brief oral presentation at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy. The data shows superior weight loss effects of the drug compared to co-administration of eloralintide and tirzepatide in a diet-induced obesity (DIO) animal model. "Based on this preclinical data, we believe that the ASC36 and ASC35 combination formulation has the potential to achieve better weight loss effects in obese individuals compared to the combination of eloralintide and tirzepatide," said Dr. Wu Jingzi, founder, Chairman, and CEO of GeneLeap. "The inclusion of this data in the oral presentation session at the EASD 2026 meeting highlights the importance of developing new treatment options for patients with obesity." ASC36_35 FDC is a once-monthly subcutaneous injection of a combination formulation of ASC36 and ASC35, which aims to target the three validated targets of insulin receptor, GLP-1R, and GIPR as a first-in-class candidate drug. The once-monthly combination formulation of ASC36_35 FDC is a self-assembled lipid depot formulation using GeneLeap's proprietary Ultra Long Acting Drug Development Platform (ULAP) technology.